Clinical TrialsThe initiation of a registration-enabling Phase 2 study for pelareorep in combination with paclitaxel in HR+/HER2- breast cancer is planned, which may enhance treatment options and improve patient outcomes.
Regulatory ProgressOncolytics Biotech is planning to launch a P2 study in breast cancer, with the intent of seeking accelerated approval, following positive feedback from the FDA.
Survival DataPositive final results from the BRACELET-1 trial showed a significant improvement in median overall survival for patients with metastatic breast cancer when treated with pelareorep plus chemotherapy.